We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Pharmacodynamic Study of ABT-436 in Major Depressive Disorder

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01380704
First Posted: June 27, 2011
Last Update Posted: November 21, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AbbVie
  Purpose
This is a multiple-dose study to assess the safety and pharmacology of ABT-436 in physically healthy subjects with mild to moderate depressive symptoms who are not taking any antidepressant medication. Efficacy for treatment of depressive symptoms is not a goal of this study.

Condition Intervention Phase
Major Depressive Disorder Drug: ABT-436 Drug: Matching Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Pharmacodynamic Effects of ABT-436 in Major Depressive Disorder Subjects

Further study details as provided by AbbVie:

Primary Outcome Measures:
  • Pharmacology assays [ Time Frame: Days -2, -1, 6, 7 ]
    Hormones in blood, urine and saliva samples

  • ABT-436 drug levels [ Time Frame: Days 6, 7 ]
    ABT-436 drug levels in plasma

  • Vital signs [ Time Frame: Days -2 through 8, 14, 30 ]
    Blood pressure, pulse

  • Clinical safety labs [ Time Frame: Days -2, 2, 5, 8 ]
    Hematology, chemistry, urinalysis


Secondary Outcome Measures:
  • Psychiatric symptom scales [ Time Frame: Days -2, 7 ]
    Hamilton depression scale, Mood and anxiety symptom questionnaire, Perceived stress scale


Enrollment: 51
Study Start Date: June 2011
Study Completion Date: September 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Active Drug: ABT-436
QD Days 1-7
Placebo Comparator: Placebo Drug: Matching Placebo
QD Days 1-7

Detailed Description:
This is a multiple-dose study to assess the safety and pharmacology of ABT-436 in physically healthy subjects with mild to moderate depressive symptoms who are not taking any antidepressant medication. Efficacy for treatment of depressive symptoms is not a goal of this study. Fifty subjects will receive study drug for seven days. Thirty subjects will receive ABT-436 and twenty subjects will receive placebo. Blood, urine and saliva samples will be obtained, both before and during study drug administration, to measure ABT-436 pharmacology. Safety will be assessed throughout the study, including at two follow-up visits after completion of study drug administration.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

1. Age between 18 to 55 years, inclusive. 2. Body Mass Index is 20 to 35 kg/m2, inclusive. 3. A primary Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition, Text Revision (DSM-IV-TR) diagnosis of major depressive disorder.

4. Mild-to-moderate depressive symptoms at Screening. 5. A condition of general good physical health. Exclusion Criteria

  1. Pregnant or breast-feeding female.
  2. Use of any medication within 4 weeks prior to Day -2, unless the dose has been stable for 4 weeks, no dose change is anticipated during the study, and the medication is specifically allowed for this study, OR prior as needed (PRN) use of the medication is specifically allowed for this study.
  3. Use of fluoxetine or aripiprazole within 8 weeks prior to Day -2.
  4. Positive screen for drugs of abuse/alcohol, recent history of drug/alcohol abuse or smoking.
  5. A current or past history of major depressive disorder with psychotic features, bipolar disorder, schizophrenia or other psychotic disorder, mental retardation, or mental disorder due to a general medical condition.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01380704


Sponsors and Collaborators
AbbVie
Investigators
Study Director: Katherine Tracy, MD Abbott
  More Information

Publications:
Responsible Party: AbbVie
ClinicalTrials.gov Identifier: NCT01380704     History of Changes
Other Study ID Numbers: M12-674
First Submitted: June 1, 2011
First Posted: June 27, 2011
Last Update Posted: November 21, 2017
Last Verified: November 2011

Keywords provided by AbbVie:
Depression

Additional relevant MeSH terms:
Disease
Depressive Disorder
Depression
Depressive Disorder, Major
Pathologic Processes
Mood Disorders
Mental Disorders
Behavioral Symptoms